2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And AnalysisGlioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue.
Request Sample Report:
https://precisionbusinessinsights.com/request-sample?product_id=16248
The global glioblastoma multiforme treatment market is growing at a significant rate due to increase in the geriatric population, and changes in the lifestyle. The increase in alcohol consumption, a rise in malaria prevalence, and the increase in the incidence of seizures are the key factors driving the global glioblastoma multiforme treatment market. In addition to that, increased R & D in gene therapy, molecular biotechnology for the treatment of CNS associated disorders, urgent need of alternative treatment procedures due to the resistance of glioma cells to conventional therapies are anticipated to boost the glioblastoma treatment market.
However, major restraints of the glioblastoma multiforme disease market are current treatment therapies such as radiation and chemotherapy does not prevent tumor recurrence that causes death in glioblastoma multiforme patients. Similarly, high expenditure for the genomics-based research, less number of drugs available in the market, and the high cost of treatment are expected to hinder the glioblastoma multiforme treatment market growth.
The global Glioblastoma multiforme treatment market is divided into following categories-
1. Drug type
• Temozolomide
• Bevacozumab
• carmustine
• Radiosensitizers
• Others
2. End-users
Hospital, retail and online pharmacies
And lastly on the basis of geographical regions, the glioblastoma treatment market segmented into following regions- North America, Asia-Pacific, Europe, the Middle East & Africa, and Latin America. North America dominates the glioblastoma multiforme disease market followed by Europe and Asia-Pacific. North America region growth is attributed to increase in the prevalence of glioblastoma multiforme disease, investments in R &D, and increasing CNS cancers in aging population. Company’s betting heavily on research activities due to lack of drugs to treat glioblastoma multiforme in the market.
Similarly, National Brain Tumor Society, Brain Tumor Foundation of Canada, and American Brain Tumor Association are the health organizations engaged in raising awareness about glioblastoma multiforme leading to the growth of glioblastoma multiforme treatment market. Europe glioblastoma multiforme disease market revenue growth is driven by increase in geriatric population, change in lifestyle and increase in research and development activities by various pharmaceutical companies. Asia-Pacific is expected to be the fastest growing market due to improved healthcare infrastructure, and rising awareness of glioblastoma multiforme treatment.
Some of the key players in global glioblastoma multiforme treatment market are Merck & Co Inc. (U.S.), Teva Pharmaceutical Industries, Ltd. (Israel), Arbor Pharmaceuticals LLC. (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Celldex Therapeutics, Inc. (U.S.), Bristol-Myers Squibb Co. (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc. (U.K.), Apogenix (Germany), Pfizer, Inc. (U.S.), and Vascular Biogenics (Israel) to name a few. In 2015, CANbridge Life Sciences acquired license for to develop, manufacture and commercialize Apogenix’s APG101 onco-immunotherapy in glioblastoma for China.
Increase in prevalence of brain tumors driving the growth of glioblastoma multiforme treatment market. Moreover, various drugs which are under clinical trials are expected to fuel the growth of glioblastoma multiforme treatment market. Rising product approvals from USFDA also expected to drive revenue of glioblastoma treatment market. For e.g. in 2005, USFDA approved Temozolomide (Temodar) capsules, developed by Schering Corporation (Merck & Co., Inc.) to treat newly diagnosed patients with glioblastoma multiforme disease associated with radiotherapy and then as maintenance treatment. Similarly, entry of generics into the market also increases the growth of glioblastoma multiforme treatment market.
For More Information : https://precisionbusinessinsights.com/market-reports/global-glioblastoma-multiforme-treatment-market/
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market here
News-ID: 1609747 • Views: …
More Releases from Precision Business Insights
Consumer 3D Printing Market Adopting New Technology for Mass Production
According to Precision Business Insights (PBI), the latest report, the market value of the consumer 3d printing market size was valued at USD 16.7 billion in 2023, growing at a 22.3% CAGR from 2024 to 2030 The primary factors that drive the market are the growing 3D modelling technology for production of various items, increasing demand for 3d printers for complex structure printing.
View The Detailed Report Description Here - https://www.precisionbusinessinsights.com/market-reports/consumer-3d-printing-market…
Grain Processing Equipment Market Increasing in Development of Automatic and Sem …
According to Precision Business Insights (PBI), the latest report, the market value of the grain processing equipment market size was valued at USD 6.2 billion in 2023 and is projected to reach USD 18.5 billion by 2029, growing at a 5.2% CAGR from 2024 to 2030. The primary factors that drive the market are the adoption of technology in the agriculture sector with automatic and semi-automatic machinery, rising quality production…
Home Textiles Market Growth Drivers, Trends and Regional Analysis 2024
According to Precision Business Insights (PBI), the latest report, the market value of the home textiles market size was valued at USD 114.5 Billion in 2023, growing at a CAGR of 7.2% from 2024 to 2030. The main factors that drive the market are the growing home décor preferences as a result increased in home textile market, rising development of real estate, and increasing demand for home furnishing.
View Full Report:…
Green Ammonia Market Analysis Current Landscape and Future Outlook 2024
According to Precision Business Insights (PBI), the latest report, the market value of the green ammonia market size was valued at USD 382.3 million in 2023 and is projected to grow at an 29.2% CAGR during the forecast period 2024 to 2030. The main factors that drive the market are the growing awareness about renewable energy resources, decrease in natural gas availability peoples are shifting towards green energy with zero…
More Releases for Glioblastoma
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)…
Glioblastoma Treatment Drugs Market : Drivers, Restraint & Future Growth
Brain tumors is one of the leading cause of cancer which is common among children and teenagers. Glioblastoma (GBM) is most common grade four tumor, is malignant and contains dead tumor cells. It is also called as Glioblastoma multiforme, it has variants of giant cell Glioblastoma and gliosarcoma found in cerebral hemisphere of brain. The exact cause of this tumor is not known but is also found in spinal cord…
Glioblastoma Multiforme Treatment Market : Global Glioblastoma Multiforme Treatm …
Glioblastoma Multiforme Treatment Market
Precision Business Insights (PBI) in its report titled “Global Glioblastoma Multiforme Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
Glioblastoma multiforme is the high-grade glioma and…
Glioblastoma Multiforme Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial…
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging…
2024 Market Size And Company Share Data For Glioblastoma
"The Latest Research Report OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Glioblastoma Market
Glioblastoma multiforme (GBM) is characterized as a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to…